Company news

Invivyd, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

May 6, 2024

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

May 1, 2024

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

April 29, 2024

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

April 14, 2024

Invivyd Announces CEO Transition

April 11, 2024

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

April 3, 2024

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

March 27, 2024

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

March 21, 2024

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

March 21, 2024

Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

February 4, 2024

Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents

January 2, 2024

Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

December 17, 2023

Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights

November 8, 2023

Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights

November 1, 2023

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19

September 10, 2023

Invivyd Appoints William Duke as Chief Financial Officer

September 4, 2023

Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights

August 9, 2023

Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights

August 2, 2023

Invivyd Announces Appointment of Sara Cotter to Board Of Directors

July 26, 2023

Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

July 16, 2023

Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19

June 25, 2023

Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

June 21, 2023

Invivyd Reports First Quarter 2023 Financial Results and Business Highlights

May 10, 2023

Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update

April 24, 2023

Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer

April 11, 2023

Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19

March 29, 2023

Invivyd Reports Full Year 2022 Financial Results and Business Highlights

March 22, 2023

Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies

March 5, 2023

Invivyd Announces Changes to Executive Team

February 2, 2023

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

December 5, 2022

Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19

November 16, 2022

Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights

November 9, 2022

Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights

November 1, 2022

Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors

October 23, 2022

Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform

October 12, 2022

Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022

October 11, 2022

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants

September 11, 2022

← Newer news releases

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 29 decks. Every deck is listed under its year.